EU Decision for Translarna Has Positive Read Through for Sarepta (SRPT) - Credit Suisse

November 14, 2016 6:28 AM EST
Get Alerts SRPT Hot Sheet
Price: $32.66 -5.31%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Credit Suisse analyst Alethia Young said the CHMP decision to leave PTC's DMD drug Translarna with conditional approval on market in Europe is a positive read-through for Sarepta's (NASDAQ: SRPT) potential filing in the EU.

"At 100% probability of success, EU sales are worth $26/sh to our valuation", the analyst said.

The analyst maintained an Outperform rating and price target of $41 on SRPT.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $39.52 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Credit Suisse

Add Your Comment